LEADERSHIP TEAM
KEY ADVISORS
BOARD OF DIRECTORS
SEC FILINGS

Extract Value from Natural and Chemically Modified Compounds

Pre-clinical portfolio of microbiome-derived immune-modulating peptides and other small molecules with exclusive technologies and the scientific expertise for discovering, expanding and advancing a valuable IO/I pipeline.

Primary Strategy:

• Deep dive into metabolome
- • Concentration of minor metabolites
- • Fractionanation to simplified pools for testing
- • High rate of structured novelty
- • Priority driven by biological activity (IP created)
- • Potential to go directly to the organism
Derivative strategy:
- • Modify major metabolites
- • Novel chemistry creates IP positions
- • Abundant by-product compounds
- • One-step chemistry transforms ADME properties
- • Available for broad screening as pure compounds
- • Synthetic GMP (IP creates)
Two-prong strategy to explore pharmaceutical potential

Unprecedented Bias-Free Access to the Microbiome
that is Relevant to Human Health

Combining Novel Chemistry from the
Microbiome with Deep Analytics

RAPID AND STREAMLINED APPROACH

Extract Value from Natural and Chemically Modified Compounds

Primary Strategy:

Derivative strategy:

Two-prong strategy to explore pharmaceutical potential

Unprecedented Bias-Free Access to the Microbiome that is Relevant to Human Health

Combining Novel Chemistry from the Microbiome with Deep Analytics

RAPID AND STREAMLINED APPROACH

Pin It on Pinterest

Unprecedented Bias-Free Access to the Microbiome
that is Relevant to Human Health

Combining Novel Chemistry from the
Microbiome with Deep Analytics